Intravenous Immunoglobulin Market Overview

The Intravenous Immunoglobulin (IVIG) market was valued at approximately US$ 11,206.54 million in 2021 and is projected to grow to US$ 18,672.55 million by 2028, reflecting a compound annual growth rate (CAGR) of 7.6% from 2022 to 2028.

The growth of this market is primarily driven by the increasing incidence of immunodeficiency disorders and a rising elderly population.

Market Drivers

According to the National Institute of Allergy and Infectious Diseases (NIAID), there are over 200 types of primary immune deficiency diseases (PIDDs) affecting around 500,000 individuals in the United States. These rare genetic disorders can be chronic, debilitating, and costly to manage. One notable condition is Immune Thrombocytopenia (ITP), an autoimmune disorder that leads to dangerously low platelet levels, known as thrombocytopenia. The Rare Diseases Organization reports that approximately 200,000 new ITP cases are diagnosed globally each year.

Furthermore, demographic data from the United Nations Population Division indicates that countries in Asia and Europe have some of the oldest populations, with Japan leading at 28% of its population aged 65 and over, followed by Italy at 23%. Other countries like Finland, Portugal, and Greece also have significant elderly populations. Many patients receiving IVIG treatment are over the age of 60, and as individuals age, their ability to produce T-cells diminishes, making them more susceptible to infections and diseases. This trend significantly boosts the demand for immune therapies, including IVIG.

Segment Analysis of the Intravenous Immunoglobulin Market

The IVIG market can be categorized based on type, application, distribution channel, and end user.

By Type

The market is divided into several immunoglobulin types: IgG, IgM, IgA, IgE, and IgD. In 2021, the IgG segment dominated the market share. However, the handheld segment is expected to experience the highest CAGR during the forecast period due to the extensive use of IgG in treating various disorders.

By Application

Applications of IVIG include hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura, inflammatory myopathies, specific antibody deficiency, Guillain-Barre syndrome, and others. The segment for immunodeficiency diseases is anticipated to hold the largest market share in 2021 and is projected to grow at the fastest rate from 2022 to 2028, driven by the increasing prevalence of these diseases and more FDA approvals for IVIG products.

By Distribution Channel

The IVIG market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacy segment held the largest market share in 2021, while the retail pharmacy segment is expected to grow at the highest CAGR during the forecast period, attributed to the expansion of retail pharmacies and a shift in consumer preferences towards organized retail that offers high-quality medications.

By End User

End users of IVIG include hospitals, specialty clinics, and others. In 2021, hospitals represented the largest share of the market. However, specialty clinics are projected to see the fastest growth in demand from 2022 to 2028, thanks to advancements in these clinics that provide rapid and accurate immunoglobulin replacement therapy (IgRT) to patients.

Geographical Insights

North America currently holds the largest share of the global IVIG market, while the Asia Pacific region is recognized as the fastest-growing area. The North American market is expected to expand due to the rising incidence of immunodeficiencies and autoimmune diseases, increased R&D activities related to IVIG, and a growing demand for advanced therapeutic options.

From 2022 to 2028, the Asia Pacific region is projected to achieve the highest CAGR in the IVIG market, with significant growth anticipated in countries like China, India, and Japan. This growth is driven by an aging population, a higher prevalence of immune deficiency disorders, and a growing acceptance of immunoglobulin-based therapies.

Market Opportunities

The pharmaceutical sector is one of the most research-intensive industries in the United States, investing around 15-20% of its revenues into R&D, totaling over US$ 50 billion annually. The US leads globally in innovative R&D, contributing to over half of the new molecules developed in the past decade. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), North America accounted for 48.7% of global pharmaceutical sales in 2019, with a significant portion of new medicines launched in the US market.

India is also emerging as a key player in the global pharmaceuticals landscape, being the largest supplier of generic medications and accounting for about 20% of the global supply by volume. The Indian pharmaceutical market is valued at US$ 42 billion, ranking third in volume and thirteenth in value worldwide. Japan, with a pharmaceutical market worth US$ 107 billion, further underscores the potential for growth in the IVIG market as the global pharmaceutical industry continues to expand.

Various secondary sources, including the World Health Organization (WHO), Globocan, World Bank Data, National Health Service (NHS), National Library of Medicine (NLM), and EFPIA, were utilized in compiling this report on the global intravenous immunoglobulin market.